Skip to main content

Table 1 Summary statistics of density measures at baseline (T0) and year 1 (T1) in analysis sample A (all women included in the study)

From: Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years

 

Tamoxifen

 

No tamoxifen

 

N (unk%)

Median (IQR, range)

Mean (SD*)

 

N (unk%)

Median (IQR, range)

Mean (SD)

Visual % blinded

       

Baseline

125 (1%)

25.0 (15.0–45.0, 0.0–90.0)

32.0 (21.7)

 

171 (1%)

30.0 (15.0–47.5, 0.0–80.0)

31.6 (20.6)

T1

98 (1%)

20.0 (10.0–40.0, 0.0–90.0)

26.0 (18.8)

 

122 (2%)

30.0 (15.0–50.0, 0.0–90.0)

33.5 (22.7)

T1–T0

94 (1%)

−5.0 (−13.8–0.0, −45.0–20.0)

−6.4 (9.8, −0.66)

 

112 (2%)

0.0 (−5.0–5.0, −25.0–30.0)

−0.2 (9.6)

Visual % unblinded

       

Baseline

98 (22%)

25.0 (15.0–45.0, 0.0–95.0)

31.3 (20.5)

 

0 (100%)

  

T1

96 (3%)

20.0 (10.0–30.0, 0.0–90.0)

23.4 (18.0)

 

0 (100%)

  

T1–T0

92 (3%)

−5.0 (−12.8–5.0, −35.0–25.0)

−8.7 (9.4, −0.92)

 

0 (100%)

  

Stratus %

       

Baseline

126 (0%)

37.8 (13.5–56.8, 0.2–77.2)

34.6 (23.6)

 

172 (0%)

42.4 (9.1–58.0, 0.1–75.3)

36.2 (24.3)

T1

99 (0%)

27.6 (4.7–45.5, 0.1–67.4)

27.2 (21.3)

 

124 (0%)

42.7 (12.7–57.2, 0.1–71.0)

36.1 (23.5)

T1–T0

95 (0%)

−6.2 (−12.9–0.9, −56.5–12.0)

−7.8 (9.7, −0.81)

 

114 (0%)

−0.1 (−3.5–1.5, −27.7–56.5)

−0.2 (8.3)

Stratus DA

       

Baseline

126 (0%)

47.8 (17.2–64.7, 0.6–167.6)

46.5 (34.8)

 

172 (0%)

44.4 (16.9–67.3, 0.3–211.2)

48.3 (39.3)

T1

99 (0%)

29.9 (9.1–47.7, 0.2–128.1)

34.2 (28.9)

 

124 (0%)

42.2 (20.2–69.9, 0.3–181.5)

48.7 (38.5)

T1–T0

95 (0%)

−10.8 (−19.2–3.3, −75.5–20.3)

−13.0 (13.7, −0.95)

 

114 (0%)

−1.0 (−6.3–3.2, −54.4–108.3)

−0.5 (14.3)

Densitas %

       

Baseline

126 (0%)

41.0 (32.0–49.5, 12.0–73.0)

41.2 (12.9)

 

172 (0%)

42.0 (32.0–49.0, 10.0–72.0)

41.1 (12.3)

T1

99 (0%)

38.0 (29.0–47.0, 13.0–66.0)

37.7 (12.3)

 

124 (0%)

40.0 (34.0–50.2, 13.0–70.0)

41.4 (12.0)

T1–T0

95 (0%)

−5.0 (−8.0–1.5, −21.0–34.0)

−4.3 (7.0, −0.62)

 

114 (0%)

0.0 (−3.0–3.0, −21.0–25.0)

−0.4 (5.9)

Densitas DA

       

Baseline

126 (0%)

44.0 (32.2–57.0, 15.0–131.0)

47.5 (22.3)

 

172 (0%)

41.5 (31.0–57.0, 19.0–162.0)

47.3 (24.0)

T1

99 (0%)

36.0 (27.5–49.5, 15.0–143.0)

41.4 (20.9)

 

124 (0%)

43.0 (33.0–55.2, 19.0–157.0)

48.5 (23.3)

T1–T0

95 (0%)

−6.0 (−11.0–3.0, −35.0–103.0)

−5.8 (14.0, -0.42)

 

114 (0%)

0.0 (−3.0–4.0, −42.0–33.0)

0.1 (8.2)

Volpara %

       

Baseline

126 (0%)

8.6 (5.4–15.7, 2.2–31.4)

11.0 (6.8)

 

172 (0%)

9.5 (5.7–14.1, 2.2–29.0)

10.7 (6.2)

T1

99 (0%)

7.5 (4.7–13.0, 2.1–27.8)

9.3 (5.8)

 

124 (0%)

9.1 (5.7–15.4, 2.1–28.2)

11.0 (6.2)

T1–T0

95 (0%)

−0.9 (−2.3–0.2, −9.8–4.6)

−1.4 (2.5, −0.56)

 

114 (0%)

0.0 (−0.9–0.9, −13.9–10.4)

−0.2 (2.8)

Volpara DV

       

Baseline

126 (0%)

61.4 (43.9–86.2, 17.6–189.9)

69.4 (36.2)

 

172 (0%)

62.1 (40.6–89.1, 14.4–246.8)

70.7 (38.8)

T1

99 (0%)

49.7 (35.9–67.0, 17.5–173.1)

55.3 (27.3)

 

124 (0%)

57.5 (41.1–85.2, 11.3–196.5)

67.7 (38.4)

T1–T0

95 (0%)

−11.0 (−21.6–2.7, −74.2–26.5)

−14.2 (16.3, −0.87)

 

114 (0%)

−2.5 (−11.3–4.5, −83.5–51.0)

−3.8 (18.7)

NN-VAS %

       

Baseline

126 (0%)

41.1 (29.7–54.5, 7.1–76.8)

42.0 (16.3)

 

172 (0%)

43.8 (31.1–53.5, 8.4–76.0)

42.5 (16.1)

T1

99 (0%)

37.4 (23.6–47.0, 5.3–73.7)

36.9 (15.0)

 

124 (0%)

44.4 (31.2–54.2, 6.8–78.0)

42.5 (16.6)

T1–T0

95 (0%)

−5.3 (−8.8–2.0, −24.2–18.1)

−5.3 (5.8, −0.90)

 

114 (0%)

−0.7 (−3.6–1.0, −19.8–31.8)

−1.1 (6.0)

  1. DA dense area, DV dense volume, IQR inter-quartile range, SD standard deviation, unk unknown
  2. *T1–T0 for tamoxifen group statistic is mean (SD, mean/SD)